Key Uses and Benefits of Adenosina (Aervae Lanatae Herba)

The therapeutic application of this preparation is centered on providing supportive management within the urinary and renal systems. The focus is on addressing symptoms related to fluid clearance and the presence of mineral deposits. The plant is traditionally applied for conditions such as urolithiasis (kidney stones) and symptomatic relief of difficult urination.

This agent is commonly used to help with conditions characterized by episodic or fluctuating symptom patterns. It provides supportive assistance for managing urolithiasis and may assist with the process of passing small deposits or mineral gravel. It is also relevant for easing the discomfort associated with dysuria (painful urination) and strangury (slow flow), as well as supporting the body during temporary physiological imbalance related to fluid retention. The overall aim is to contribute to improved comfort during periods of heightened symptoms.

---

Quick Fact: Relief for Urinary Discomfort

Symptom Domain	Practical Benefit
Urolithiasis (Gravel)	May assist with the process of small stone expulsion.
Dysuria/Strangury	Helps ease burning sensation and difficulty during urination.
Fluid Retention	Supports the body in managing fluid clearance.

Adenosina is an antiarrhythmic agent whose use is strictly governed by regulatory guidelines, particularly concerning pre-existing cardiac and pulmonary conditions.

Contraindicated Populations

Use of Adenosina is contraindicated in patients with a known hypersensitivity to the drug. It must not be used in individuals with Second- or third-degree Atrio-Ventricular (AV) block or Sinus node disease (such as sick sinus syndrome or symptomatic bradycardia), unless a functioning artificial pacemaker is present. It is also prohibited for individuals with known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma). Regulatory documents in some regions also contraindicate use for patients with Long QT syndrome, severe hypotension, and decompensated heart failure.

Restricted and Cautioned Use

Use is avoided in patients showing signs or symptoms of acute myocardial ischemia. Caution is required in patients with pre-existing First-degree AV block, bundle branch block, left main coronary stenosis, uncorrected hypovolemia, and stenotic valvular heart disease. If a patient develops persistent or symptomatic high-grade AV block, severe respiratory difficulties, or persistent symptomatic hypotension, administration must be immediately discontinued.

Age and Pregnancy

Adenosina is classified as a Pregnancy Category C drug by the FDA, meaning it should be used during pregnancy only if the potential benefit justifies the potential risk. In geriatric patients, it is used with caution due to the possibility of diminished cardiac function or other concomitant conditions.

Interactions with other medicines and products

The official regulatory profile for Adenosina interactions is defined by substances that either antagonize its receptor activity or inhibit its cellular uptake and metabolism.

Key Interacting Categories and Restrictions

Category
Methylxanthines (e.g., Theophylline, Aminophylline)
Dipyridamole and other Inhibitors of Nucleoside Uptake
Xanthine-Containing Food/Drink (e.g., Caffeine)

---

Official Regulatory Statements

• Methylxanthines are non-specific adenosine receptor antagonists and may diminish the therapeutic effect of Adenosina. Regulatory instructions require the withholding of methylxanthines for a specified period prior to administration, or a larger dose of Adenosina may be necessary.
• Dipyridamole is a potent inhibitor of nucleoside uptake that significantly potentiates the effect of Adenosina. Co-administration is not recommended unless the potentiation is intentionally desired. Official labeling requires Dipyridamole to be discontinued at least 24 hours before Adenosina is administered.
• Other inhibitors of nucleoside uptake may also potentiate the effect, requiring a reduction in the initial Adenosina dose and close monitoring.
• Consumption of Xanthine-containing foods or beverages such as caffeine should be avoided for at least 12 hours before use as they can antagonize the drug's effect.

Adenosine is a naturally occurring nucleoside that acts as a purinergic signaling molecule, exerting its effects by binding to specific G protein-coupled receptors (GPCRs) found on the surface of various cells. The drug's mechanism involves modulating key cardiovascular and vascular pathways, which results in defined physiological alterations.

---

Modulating Atrioventricular Nodal Conduction

Adenosine primarily targets the Adenosine A1 receptors (A1) in cardiac tissues, particularly the atrioventricular (AV) node. Activation of the A1 receptors initiates a signaling cascade that inhibits adenylyl cyclase and activates specific inward-rectifier potassium channels, leading to hyperpolarization of the cell membrane and a reduced influx of calcium ions. This process significantly slows the electrical impulse conduction through the AV node, which results in prolonged refractoriness and decreased excitability within the AV nodal tissue.

---

Mediating Vascular Smooth Muscle Relaxation

Adenosine also engages the Adenosine A2A receptors (A2A) and A2B receptors (A2B) located on the smooth muscle cells of the peripheral vasculature, including coronary arteries. Binding to A2A receptors is the main pathway, stimulating the Gs-protein coupled pathway to increase intracellular cyclic AMP (cAMP), which causes relaxation of the vascular smooth muscle. This modification of vascular tone results in vasodilation and a resulting decrease in peripheral vascular resistance.

Official Administration Guidelines for Adenosina

Adenosina is administered only by a healthcare professional in a clinical setting where continuous cardiac monitoring and cardiopulmonary resuscitation equipment are immediately available. It is not an oral or take-home medication.

Route and Method

Administration is exclusively intravenous (IV). For the conversion of certain rapid heart rhythms (PSVT), the medicine is given as a rapid IV push over 1–3 seconds, followed immediately by a rapid flush of saline solution. This quick method ensures the medicine reaches the heart efficiently. For diagnostic testing, the medicine is administered as a continuous IV infusion over a six-minute period.

Dosing Schedule and Adjustments

Purpose	Initial Dose	Subsequent Doses (if needed)
PSVT Conversion (Adult)	6 mg rapid IV push	12 mg rapid IV push after 1–2 minutes (up to two more times)
PSVT Conversion (Pediatric)	0.05–0.1 mg/kg rapid IV push	0.2 mg/kg rapid IV push after 1–2 minutes
Diagnostic Stress Test	0.14 mg/kg/min continuous infusion for 6 minutes	Not applicable

A reduced initial dose of 3 mg rapid IV push is required for patients who have undergone a heart transplant or who are concurrently receiving certain medications, such as Dipyridamole or Carbamazepine. Pediatric dosing is based on the patient's weight.

Procedural Steps

The injection must be administered into a large peripheral vein or central line, using the most proximal port possible. The solution must be inspected for particulate matter or crystallization before use and must not be refrigerated.

Research Evidence / Overview of Studies for Adenosine

Evidence for Use in Acute Supraventricular Tachycardia (SVT)

Research has explored the use of adenosine in individuals experiencing conditions characterized by acute or disruptive episodes like Supraventricular Tachycardia (SVT). Studies conducted in emergency or clinical settings have primarily focused on observing acute changes over defined time intervals. These are mainly short-term Randomized Controlled Trials (RCTs) and comparative studies that examine rapid physiological changes following administration. Outcomes monitored include the measurement of sinus rhythm (a normal heart rhythm) and the time interval over which a change was observed.

Findings describe patterns observed in the studies, where changes in heart rhythm were measured during the immediate post-administration period in some patients. Because adenosine is quickly cleared from the body, the research highlights changes measured during the study period which is often seconds to minutes. Some comparative research has explored the outcomes of using adenosine versus other antiarrhythmic medications in the acute treatment of SVT.

Evidence for Use as a Pharmacological Stress Agent in Cardiac Imaging

Adenosine was studied for its use as a pharmacological stress agent in patients undergoing myocardial perfusion imaging (MPI), often to assess blood flow to the heart muscle. This type of research is applied in studies examining outcomes monitoring physiological strain or stress in a controlled manner, typically for individuals who are unable to perform adequate physical exercise for a standard stress test. Researchers monitored outcomes such as changes in heart rate, blood pressure, and how well the imaging procedure was able to visualize blood flow.

Studies reported that adenosine administration was associated with measurable hemodynamic changes that were monitored during the stress procedure, contributing to outcomes monitoring physiological strain or stress.

Long-Term Studies and Follow-up

Research has predominantly focused on the immediate effects of adenosine due to its rapid clearance from the body. Consequently, long-term effects are not fully established. Studies examining follow-up beyond the short, acute treatment or imaging period are limited. This means the limited information for long-term outcomes contributes to the uncertainty about the durability or lasting effects of adenosine use, particularly in the context of ongoing cardiac management.

Key Studies & References

1. Pharmacologic Stress Myocardial Perfusion Imaging: An Overview and Comparison of the Different Agents

Common questions about Adenosina (FAQ)

Q: What is Adenosina and how does it work?

A: Adenosina is a naturally occurring substance in the body that works by slowing down electrical conduction through the atrioventricular (AV) node in the heart. This action temporarily interrupts the electrical circuit that causes certain types of rapid heart rhythms, such as paroxysmal supraventricular tachycardia (PSVT), allowing the heart's normal rhythm to restart.

Q: What conditions is Adenosina used to treat?

A: Adenosina is primarily used to treat a condition called paroxysmal supraventricular tachycardia (PSVT), which is a very fast heart rate caused by abnormal electrical signaling above the lower chambers of the heart. It is used as a short-acting, injectable medication in an emergency or clinical setting to quickly restore a normal heart rhythm. It is also used during certain types of cardiac stress tests to simulate the effects of exercise when a person cannot physically exercise.

Q: How is Adenosina typically administered?

A: Adenosina is administered as a rapid intravenous (IV) injection directly into a vein, usually in a hospital or emergency setting, under the supervision of a healthcare professional. The injection is given quickly, followed immediately by a rapid flush of saline solution. This method is necessary because Adenosina acts very fast and is quickly cleared from the body.

Q: What are the common side effects of Adenosina?

A: Because Adenosina acts quickly and temporarily, its side effects are usually brief. Common side effects may include:

• A brief feeling of flushing or warmth
• Shortness of breath or chest discomfort
• A feeling of a skipped or pounding heartbeat (palpitations)
• Dizziness or lightheadedness
• A feeling of pressure in the head or neck

These effects typically resolve within a minute or two after the injection.

Q: Who should not receive Adenosina?

A: Adenosina should generally not be given to individuals who have certain pre-existing heart conditions, including:

• Second- or third-degree atrioventricular (AV) block (unless a pacemaker is in place)
• Sick sinus syndrome (unless a pacemaker is in place)
• Known severe bronchospastic lung disease, such as uncontrolled asthma

It is important to inform your healthcare provider about all of your medical conditions before receiving this medication.

How to Store and Dispose of Adenosina

Storing Adenosina correctly ensures its effectiveness and stability, as defined by regulatory standards.

Official Storage Requirements

Condition	Requirement
Storage Temperature	Store at Controlled Room Temperature, typically 20° to 25°C (68° to 77°F).
Handling Constraints	Do not refrigerate or freeze, as this may cause crystallization. If crystals form, they must be dissolved by warming the container to room temperature. The solution must be clear before use.
In-Use Stability	The medicine should be used immediately after opening. Any unused portion must be discarded.
Protection	Keep this medicine out of the reach and sight of children.

Disposal Instructions

Adenosina must not be disposed of via wastewater or regular household waste. Used or expired product must be disposed of in accordance with local requirements and regulations to help protect the environment.